Rep. Gilbert Cisneros Buys Shares of STERIS plc
Rep. Cisneros purchased STERIS shares valued between $1,001 and $15,000 in May.
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| STERIS plc ($STE) | Buy | May 11, 2026 | $1,001 - $15,000 |
Key Points
- U.S. Representative Gilbert Cisneros purchased STERIS shares valued between $1,001 and $15,000 on May 11, 2026.
- STERIS plc, listed on NYSE under STE, has a market cap of $20.2 billion and a P/E ratio of 26.17.
- Insiders including CEO Daniel Carestio sold shares in early June, while analysts maintain a 'buy' rating with a target price of $256.86.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
U.S. Representative Gilbert Cisneros recently disclosed a purchase of shares in STERIS plc, a medical devices company listed on the NYSE under the ticker STE. The transaction, which took place on May 11, 2026, involved a buy valued between $1,001 and $15,000 as reported on June 9, 2026. This purchase is part of periodic transaction reports required under the STOCK Act.
Gilbert Cisneros vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
STERIS plc Stock Down 11.9%
Shares of NYSE:STE traded near $207.56 recently. STERIS plc, known for providing infection prevention products and services, has a market capitalization of about $20.2 billion. The stock's P/E ratio stands at 26.17, with a forward P/E of 17.14, indicating investor expectations of growth. STERIS has a 52-week low of $195.14 and a high of $269.44, with a 50-day moving average of $215.95 and a 200-day moving average of $239.71. The company maintains a healthy current ratio of 2.09 and a quick ratio of 1.34, with a debt-to-equity ratio of 29.0.
Recent Earnings
STERIS reported revenues of approximately $5.94 billion, with a revenue growth rate of 7.3%. The company's net margin is 13.2%, and it achieved a return on equity of 11.4%. The earnings per share (EPS) is $7.93. Investors will be watching for the next earnings report on August 5, 2026.
Dividend
STERIS pays an annual dividend of $2.52, yielding 1.21%. The dividend payout ratio is 31.02%, indicating a stable return to shareholders. The company supports this with robust cash flows from its operations.
Insider Buying and Selling at STERIS plc
In early June, several STERIS insiders sold shares. President and CEO Daniel Carestio sold 1,374 shares at an average price of $212 under a Rule 10b5-1 plan on June 5, 2026. Other executives, including Sr. VP and GM Julia Madsen, also sold shares around the same time.
Analysts Set New Price Targets
On May 13, 2026, Keybanc maintained its 'buy' rating for STERIS, setting a price target of $269. The consensus among analysts is a 'buy' rating, with an average target price of $256.86 based on seven analyst opinions.
About STERIS plc
STERIS plc is a healthcare company based in Mentor, Ohio, specializing in infection prevention products and services. It operates in the Healthcare, Applied Sterilization Technologies, and Life Sciences segments, offering a range of sterilization and cleaning solutions. Led by CEO Daniel A. Carestio, the company employs over 17,900 people and serves healthcare providers and manufacturers worldwide.
Bottom Line
The purchase by Rep. Cisneros highlights ongoing interest in STERIS plc, a company with strong financial metrics and a solid market position. While the 13F filings and insider trades provide a backward-looking view, they remain vital for understanding institutional and insider confidence in the stock. Investors and analysts will continue to monitor STERIS's performance and strategic decisions closely.
Get STERIS plc alerts
New 13F filings, insider trades, and analyst moves on $STE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.